Fundraising Fox
Invivyd
NASDAQ: IVVDUnicorn · $1.5BWaltham, US · Founded 2020 · 18 known investors
Find your way into Invivyd
Sign up to see every warm intro you have to Invivyd
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Invivyd team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering. Its pipeline starts with COVID-19 and aims to expand into influenza and other high-need indications.
Founders & leadership
Invivyd was founded in 2020 by Tillman U. Gerngross and Marc Elia.
Board
Investors · 18
How we know: Bain Capital Life Sciences's portfolio page · Not right? Tell us
How we know: Foresite Capital's portfolio page · bostonglobe.com · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · the S-1 prospectus · funding news · bostonglobe.com · Not right? Tell us
How we know: MRL Ventures Fund's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · the S-1 prospectus · a partner's Signal profile · bostonglobe.com · Not right? Tell us
How we know: board seat on SEC Form D · funding news · bostonglobe.com · Not right? Tell us
How we know: bostonglobe.com · Not right? Tell us
How we know: the S-1 prospectus · bostonglobe.com · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: bostonglobe.com · Not right? Tell us
Also in the syndicate · 5
Reported raises · per SEC filings
Form D private placements$489.1M disclosed across 4 of 7 rounds · 1900–2022
▶$23.7MraisedNov 2022 · 1 investors · BiotechnologyRule 506(b)
- Michael S. WyzgaDirector
- Fred DriscollExecutive Officer
- Tamsin BerryDirector
- Christine LindenboomDirector
- Terry McGuireDirector
- Rebecca DaboraExecutive Officer
- Marc EliaDirector
- Jill AndersenExecutive Officer
- Clive A. MeanwellDirector
- David HeringExecutive Officer, Director
- Ellie HershbergerExecutive Officer
- Tom HeymanDirector
- Offering amount
- $23.7M
- Amount sold
- $23.7M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$335.5MraisedApr 2021 · 36 investors · BiotechnologyRule 506(b)
- Lynn ConnollyExecutive Officer
- Eric KimbleExecutive Officer
- Halley GilbertExecutive Officer
- Terrance McGuireDirector
- Rebecca DaboraExecutive Officer
- Rene RussoDirector
- Howard MayerDirector
- Philip ChaseDirector
- Ellie HershbergerExecutive Officer
- Ajay RoyanDirector
- Tillman U. GerngrossExecutive Officer, Director
- Jane HendersonExecutive Officer
- Laura WalkerExecutive Officer
- Offering amount
- $335.5M
- Amount sold
- $335.5M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$80MraisedNov 2020 · 16 investors · BiotechnologyRule 506(b)
- Halley GilbertExecutive Officer
- Howard MayerDirector
- Marc EliaDirector
- Rene RussoDirector
- Terrance G. McGuireDirector
- Ajay RoyanDirector
- Philip T. ChaseDirector
- Tillman U. GerngrossExecutive Officer, Director
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$49.9MraisedNov 2020 · 24 investors · BiotechnologyRule 506(b)
- Halley GilbertExecutive Officer
- Terrance G. McGuireDirector
- Rene RussoDirector
- Marc EliaDirector
- Philip T. ChaseDirector
- Tillman U. GerngrossExecutive Officer, Director
- Ajay RoyanDirector
- Howard MayerDirector
- Offering amount
- $49.9M
- Amount sold
- $49.9M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
2 people who came through Invivyd went on to found or lead other companies.
Related companies · 4
Companies working in the same space as Invivyd.
In the news
Frequently asked questions
- What does Invivyd do?
- Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering. Its pipeline starts with COVID-19 and aims to expand into influenza and other high-need indications.
- Who founded Invivyd?
- Invivyd was founded by Tillman U. Gerngross, Marc Elia in 2020.
- Who are Invivyd's investors?
- Invivyd's investors include Bain Capital Life Sciences, Foresite Capital, GV (Google Ventures), MRL Ventures Fund, Premji Invest, RA Capital, Fidelity Investments, Mithril Capital Management and 5 more.
- How much funding has Invivyd raised?
- Invivyd has disclosed $489.1M raised across 4 of its 7 known rounds.
- Where is Invivyd headquartered?
- Invivyd is headquartered in Waltham, US.